Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples
Viruses · 25.07.2024 · 16 (8) · 1190
DOI: 10.3390/v16081190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 25.07.2024. Verfasst von Sandhya Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical Engineering and Computer Science, Florida Atlantic University, Boca Raton, FL 33431, USA. Hauptthemen laut MEDLINE: Saliva, SARS-CoV-2, Nasopharynx, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Science Foundation, National Institute of Health (NIH).
Abstract (Originalsprache)
The novel coronavirus SARS-CoV-2 was first isolated in late 2019; it has spread to all continents, infected over 700 million people, and caused over 7 million deaths worldwide to date. The high transmissibility of the virus and the emergence of novel strains with altered pathogenicity and potential resistance to therapeutics and vaccines are major challenges in the study and treatment of the virus. Ongoing screening efforts aim to identify new cases to monitor the spread of the virus and help determine the danger connected to the emergence of new variants. Given its sensitivity and specificity, nucleic acid amplification tests (NAATs) such as RT-qPCR are the gold standard for SARS-CoV-2 detection. However, due to high costs, complexity, and unavailability in low-resource and point-of-care (POC) settings, the available RT-qPCR assays cannot match global testing demands. An alternative NAAT, RT-LAMP-based SARS-CoV-2 detection offers scalable, low-cost, and rapid testing capabilities. We have developed an automated RT-LAMP-based microfluidic chip that combines the RNA isolation, purification, and amplification steps on the same device and enables the visual detection of SARS-CoV-2 within 40 min from saliva and nasopharyngeal samples. The entire assay is executed inside a uniquely designed, inexpensive disposable microfluidic chip, where assay components and reagents have been optimized to provide precise and qualitative results and can be effectively deployed in POC settings. Furthermore, this technology could be easily adapted for other novel emerging viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electrical Engineering and Computer Science, Florida Atlantic University, Boca Raton, FL 33431, USA.
- Asghar-Lab, Micro and Nanotechnology in Medicine, College of Engineering and Computer Science, Boca Raton, FL 33431, USA.
- Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
- Department of Biological Sciences (Courtesy Appointment), Florida Atlantic University, Boca Raton, FL 33431, USA.
ORCID-Profile: Waseem Asghar
Förderung
- NIAID NIH HHS
- National Science Foundation
- National Institute of Health (NIH)
Zitieren
APA
Sharma, S., Caputi, M., & Asghar, W. (2024). Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples. Viruses, 16(8), 1190. https://doi.org/10.3390/v16081190
Vancouver
Sharma S, Caputi M, Asghar W. Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples. Viruses. 2024;16(8):1190. doi:10.3390/v16081190
BibTeX
@article{Sharma2024,
author = {Sharma, Sandhya and Caputi, Massimo and Asghar, Waseem},
title = {Development of a Diagnostic Microfluidic Chip for SARS-CoV-2 Detection in Saliva and Nasopharyngeal Samples},
journal = {Viruses},
year = {2024},
volume = {16},
number = {8},
pages = {1190},
doi = {10.3390/v16081190}
}
EUVIMED